These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8508282)

  • 1. The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo.
    Porter DR; Capell HA
    Br J Rheumatol; 1993 Jun; 32(6):463-6. PubMed ID: 8508282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of homeopathy in rheumatoid arthritis.
    Fisher P; Scott DL
    Rheumatology (Oxford); 2001 Sep; 40(9):1052-5. PubMed ID: 11561118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.
    Paulus HE; Egger MJ; Ward JR; Williams HJ
    Arthritis Rheum; 1990 Apr; 33(4):477-84. PubMed ID: 2109613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
    Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A
    Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.
    Choy EH; Kingsley GH; Khoshaba B; Pipitone N; Scott DL;
    Ann Rheum Dis; 2005 Sep; 64(9):1288-93. PubMed ID: 15760929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ileum-targeted steroid therapy in rheumatoid arthritis: double-blind, placebo-controlled trial of controlled-release budesonide.
    Sheldon P
    Rheumatol Int; 2003 Jul; 23(4):154-8. PubMed ID: 12856138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis.
    Hansen TM; Kryger P; Elling H; Haar D; Kreutzfeldt M; Ingeman-Nielsen MW; Olsson AT; Pedersen C; Rahbek A; Tvede N
    BMJ; 1990 Aug; 301(6746):268-70. PubMed ID: 2202458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
    Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
    J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial.
    Javadi F; Ahmadzadeh A; Eghtesadi S; Aryaeian N; Zabihiyeganeh M; Rahimi Foroushani A; Jazayeri S
    J Am Coll Nutr; 2017 Jan; 36(1):9-15. PubMed ID: 27710596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial.
    Furuzawa-Carballeda J; Fenutria-Ausmequet R; Gil-Espinosa V; Lozano-Soto F; Teliz-Meneses MA; Romero-Trejo C; Alcocer-Varela J
    Clin Exp Rheumatol; 2006; 24(5):514-20. PubMed ID: 17181919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2018 Nov; 21(11):1977-1985. PubMed ID: 27452347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does active treatment of rheumatoid arthritis limit disease-associated bone loss?
    Dolan AL; Moniz C; Abraha H; Pitt P
    Rheumatology (Oxford); 2002 Sep; 41(9):1047-51. PubMed ID: 12209040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.
    Amalraj A; Varma K; Jacob J; Divya C; Kunnumakkara AB; Stohs SJ; Gopi S
    J Med Food; 2017 Oct; 20(10):1022-1030. PubMed ID: 28850308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
    Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.